Key Takeaways
- Jaguar Health has filed a patent application for crofelemer to address gastrointestinal side effects of GLP-1 weight loss drugs.
- Up to 85% of GLP-1 users experience digestive issues, including diarrhea, bloating, and abdominal pain.
- Crofelemer, already FDA-approved for HIV-related diarrhea, could help patients tolerate GLP-1 therapies more effectively.
Jaguar Health Inc. (NASDAQ: JAGX) has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its plant-based prescription drug, crofelemer, to reduce gastrointestinal (GI) side effects linked to GLP-1 receptor agonists and other weight loss treatments.
GLP-1 drugs, such as semaglutide and tirzepatide, have become widely used for obesity and diabetes management, but up to 85% of patients report GI-related issues, including diarrhea, bloating, and nausea. These side effects often lead to dose reductions or discontinuation of treatment. Crofelemer, already FDA-approved under the brand name Mytesi® for HIV-related diarrhea, has shown potential in improving intestinal health and could provide a safe, long-term solution for patients on GLP-1 therapies.
Targeting a Growing Market with an Innovative Approach
With the GLP-1 therapy market projected to surpass $322 billion by 2034, addressing treatment-related GI issues is critical for patient adherence and comfort. Jaguar Health believes crofelemer’s unique plant-derived formulationcould help normalize digestive function in patients using GLP-1 and incretin-based treatments, allowing them to stay on therapy without severe discomfort.
By leveraging its expertise in plant-based pharmaceuticals, Jaguar Health is positioning itself at the forefront of gastrointestinal treatment innovation, ensuring better outcomes for obesity and diabetes patients worldwide.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
